MYD88 and diffuse large B-cell lymphoma: These four genes (PIM1, MYD88, TP53, TNFAIP3) has been identified to be the mutational drivers in DLBCL, which might partly explain the poor prognosis of patients carrying PCLO mutations (32–35).